Hospitalization rates for complications due to systemic therapy in the United States

14Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The aim of this study was to estimate the trends and burdens associated with systemic therapy-related hospitalizations, using nationally representative data. National Inpatient Sample data from 2005 to 2016 was used to identify systemic therapy-related complications using ICD-9 and ICD-10 external causes-of-injury codes. The primary outcome was hospitalization rates, while secondary outcomes were cost and in-hospital mortality. Overall, there were 443,222,223 hospitalizations during the study period, of which 2,419,722 were due to complications of systemic therapy. The average annual percentage change of these hospitalizations was 8.1%, compared to − 0.5% for general hospitalizations. The three most common causes for hospitalization were anemia (12.8%), neutropenia (10.8%), and sepsis (7.8%). Hospitalization rates had the highest relative increases for sepsis (1.9-fold) and acute kidney injury (1.6-fold), and the highest relative decrease for dehydration (0.21-fold) and fever of unknown origin (0.35-fold). Complications with the highest total charges were anemia ($4.6 billion), neutropenia ($3.0 billion), and sepsis ($2.5 billion). The leading causes of in-hospital mortality associated with systemic therapy were sepsis (15.8%), pneumonia (7.6%), and acute kidney injury (7.0%). Promoting initiatives such as rule OP-35, improving access to and providing coordinated care, developing systems leading to early identification and management of symptoms, and expanding urgent care access, can decrease these hospitalizations and the burden they carry on the healthcare system.

References Powered by Scopus

Recent developments in radiotherapy

341Citations
N/AReaders
Get full text

The epidemiology of sepsis in patients with malignancy

243Citations
N/AReaders
Get full text

With Great Power Comes Great Responsibility: Big Data Research from the National Inpatient Sample

239Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study

19Citations
N/AReaders
Get full text

Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study

18Citations
N/AReaders
Get full text

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Saxena, A., Rubens, M., Ramamoorthy, V., Tonse, R., Veledar, E., McGranaghan, P., … Kotecha, R. (2021). Hospitalization rates for complications due to systemic therapy in the United States. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-86911-x

Readers' Seniority

Tooltip

Researcher 7

50%

PhD / Post grad / Masters / Doc 5

36%

Professor / Associate Prof. 1

7%

Lecturer / Post doc 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

69%

Biochemistry, Genetics and Molecular Bi... 2

15%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Computer Science 1

8%

Save time finding and organizing research with Mendeley

Sign up for free